NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension
Yumin Qiu et al. · Signal Transduction and Targeted Therapy · 2023
Evidence type: Early human interventionInterpretive weight: LimitedResearch area: Hypertension and vascular mechanisms
DesignTranslational study with a prospective randomized open-label 2-arm human intervention plus observational human, mouse, and cellular experiments; the publication is internally inconsistent on intervention duration (Methods: 30 days; Results: 6 weeks)
PopulationAdults with hypertension in the clinical component
InterventionHuman component: NMN 800 mg once daily plus lifestyle modification versus lifestyle modification alone; Methods specify 30 days, while the Results text describes outcomes after 6 weeks
EndpointsBlood pressure; Vascular endothelial function and arterial stiffness; PBMC NAD+; CD38-related mechanistic measures; Mouse and cell mechanistic endpoints
What the publication reported
This translational paper studied the relationship between CD38, NAD+ depletion, hypertension and vascular dysfunction using human participants, hypertensive mouse models and cellular experiments.
In the small randomized human component, NMN supplementation added to lifestyle intervention was associated with lower blood pressure and improved vascular measures compared with lifestyle intervention alone. The broader paper proposes a CD38-driven mechanism linking inflammation, NAD+ depletion and vascular dysfunction.
The human trial was small and embedded within a large mechanistic study, so its treatment findings should be considered early clinical evidence rather than a definitive hypertension result.
Key findings
Hypertensive participants had lower NAD+ measures alongside vascular dysfunction in the observational comparisons.
The human intervention component reported blood-pressure and vascular improvements with NMN plus lifestyle intervention.
Mouse and cell experiments implicated endothelial CD38 upregulation and accelerated NAD+ degradation in vascular dysfunction.
CD38 inhibition, genetic manipulation and NAD boosting improved vascular phenotypes in preclinical models.
The human intervention sample was small.
What it cannot establish
The randomized human intervention was small, with 19 completers.
The paper combines observational, interventional and preclinical evidence, so mechanistic certainty in humans should not be overstated.
The clinical intervention was compared with lifestyle intervention rather than a large, standalone placebo-controlled efficacy trial.
Mechanistic animal and cell results cannot be assumed to translate directly to routine NMN supplementation in humans.
HealthspanX claim boundary: This record does not establish NMN as a treatment for hypertension or cardiovascular disease. Human efficacy requires larger, independently replicated clinical trials.
